Wayne S Springate insider trades: Hemispherx Biopharma (HEB) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Wayne reports to the SEC
Open-market buys and sales
7 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 21, 2019 | HEB | ↑ Buy | 5,211 | $4.03 | $21K | Direct | Jun 24, 2019 (3d) |
| Jul 23, 2018 | HEB | ↑ Buy | 32,259 | $0.31 | $10K | Direct | Jul 23, 2018 (0d) |
| May 2, 2017 | HEB | ↑ Buy | 15,873 | $0.63 | $10K | Direct | May 3, 2017 (1d) |
| Feb 16, 2017 | HEB | ↑ Buy | 8,014 | $0.46 | $4K | Direct | Feb 21, 2017 (5d) |
| Jun 15, 2010 | HEB | ↑ Buy | 185,748 | $0.59 | $110K | Direct | Jun 16, 2010 (1d) |
| Jun 15, 2010 | HEB | ↓ Sell | 83,104 | $0.59 | $49K | Direct | Jun 16, 2010 (1d) |
| Dec 15, 2009 | HEB | ↑ Buy | 877 | $0.56 | $493 | Direct | Dec 16, 2009 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Wayne S Springate's insider trades
Wayne S Springate is Sr. VP of Operations at Hemispherx Biopharma (HEB). Since Dec 15, 2009, Wayne has reported 6 open-market purchases worth $155K and 1 sale worth $49K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (25 filings), other transactions (5 filings), conversions (1 filing), option exercises (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every HEB insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.